NCT06363708

Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer

Tislelizumab Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Endometrial Cancer : A Prospective, Single-arm, Open-label Clinical Study

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Zhongnan Hospital · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of tislelizumab in combination with chemotherapy as a neoadjuvant treatment for advanced endometrial cancer.

Detailed description

This is a multicenter, prospective, single-arm open-label study designed to enhance surgical R0 resection rate, reduce residual lesions, decrease distant metastasis and disease recurrence rates, and prolong the survival of patients with advanced endometrial cancer (stage III-IVb FIGO 2023) by neoadjuvant chemotherapy combined with tislelizumab.

Conditions

• Endometrial Neoplasms

Interventions

Type	Name	Description
DRUG	Tislelizumab	Tislelizumab 200mg D1 ,Q3W
DRUG	Paclitaxel	Paclitaxel(175 mg/m2 ) D1,Q3W
DRUG	Carboplatin	Carboplatin(AUC=5) D1,Q3W

Timeline

• Start date: 2024-06-01
• Primary completion: 2025-12-01
• Completion: 2026-06-30
• First posted: 2024-04-12
• Last updated: 2024-04-12

Locations

3 sites across 1 country: China